Frequency of mutations in drug resistant Mycobacterium tuberculosis causing extrapulmonary tuberculosis

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

The authors received no funding for the study.

Authors’ contributions

P.D. designed the study, analyzed data, critically revised the manuscript, approved final version. A.R. critically revised the manuscript. N.P. wrote the manuscript, acquired, analyzed and interpreted the data. R.P.P. acquired, analyzed and interpreted the data. S.A. critically revised the manuscript for important intellectual inputs.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Unver Ulusoy T, Duyar Agca F, Demirköse H, Karakoc Parlayan HN, Altın N, Bulut D, et al. Comparative analysis of pulmonary and extrapulmonary tuberculosis: A seven-year experience from a refugee host country, Turkiye. Asian Pac J Trop Med 2024; 17(11): 508-515.

[2] World Health Organization. Line probe assays for drug resistant tuberculosis detection, interpretation and reporting guide for laboratory staff and clinicians: Global laboratory initiative, advancing TB diagnosis. [Online]. Available from: https://stoptb.org/wg/gli/assets/documents/LPA_test_web_ready.pdf. [Accessed on 1 October 2024].

[3] Diriba G, Kebede A, Tola HH, Alemu A, Yenew B, Moga S, et al. Utility of line probe assay in detecting drug resistance and the associated mutations in patients with extrapulmonary tuberculosis in Addis Ababa, Ethiopia. SAGE Open Med 2022; 10: 20503121221098241. doi: 10.1177/20503121221098241.

[4] Jayalakshmi S, Kar H, Hodiwala AVB, Wagh S, Patil MS. Evaluation of rpoβ gene and its various mutants in multidrug-resistant tuberculosis cases by GeneXpert method. Cureus 2022; 14(11): e31249. doi: 10.7759/cureus.31249.

[5] Kabir S, Junaid K, Rehman A. Variations in rifampicin and isoniazid resistance associated genetic mutations among drug naïve and recurrence cases of pulmonary tuberculosis. Int J Infect Dis 2021; 103: 56-61. doi: 10.1016/j.ijid.2020.11.007.

[6] Desikan P, Kharate A, Panwalkar N, Khurana J, Mirza SB, Chaturvedi A, et al. Frequency of mutations in rifampicin and isoniazid resistant isolates of M. tuberculosis: An analysis from Central India. Germs 2016; 6(4): 125-131. doi: 10.11599/germs.2016.1096.

[7] Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA, et al. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20(8): 1099-1104. doi: 10.5588/ijtld.15.0864.

[8] Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, et al. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerg Microbes Infect 2018; 7(1): 183. doi: 10.1038/s41426-018-0184-0.

[9] Rostamian M, Kooti S, Abiri R, Khazayel S, Kadivarian S, Borji S, et al. Prevalence of Mycobacterium tuberculosis mutations associated with isoniazid and rifampicin resistance: A systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis 2023; 32: 100379. doi: 10.1016/j.jctube.2023.100379.

[10] Seid A, Kassa M, Girma Y, Dereb E, Nureddin S, Abebe A, et al. Molecular characterization of genetic mutations with fitness loss in pulmonary tuberculosis patients associated with HIV co-infection in Northwest Amhara, Ethiopia. SAGE Open Med 2023; 11: 20503121231208266. doi: 10.1177/20503121231208266.